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ABSTRACT
Introduction: Acute respiratory infections (ARIs) are
leading causes of hospitalisation in Australian children
and, if recurrent, are associated with increased risk of
chronic pulmonary disorders later in life. Chronic
(>4 weeks) cough in children following ARI is
associated with decreased quality-of-life scores and
increased health and societal economic costs. We will
determine whether a validated evidence-based cough
algorithm, initiated when chronic cough is first
diagnosed after presentation with ARI, improves clinical
outcomes in children compared with usual care.
Methods and analysis: A multicentre, parallel group,
open-label, randomised controlled trial, nested within a
prospective cohort study in Southeast Queensland,
Australia, is underway. 750 children aged <15 years will be
enrolled and followed weekly for 8 weeks after presenting
with an ARI with cough. 214 children from this cohort
with persistent cough at day 28 will be randomised to
either early initiation of a cough management algorithm or
usual care (107 per group). Randomisation is stratified by
reason for presentation, site and total cough duration at
day 28 (<6 and ≥6 weeks). Demographic details, risk
factors, clinical histories, examination findings, cost-of-
illness data, an anterior nasal swab and parent and child
exhaled carbon monoxide levels (when age appropriate)
are collected at enrolment. Weekly contacts will collect
cough status and cost-of-illness data. Additional nasal
swabs are collected at days 28 and 56. The primary
outcome is time-to-cough resolution. Secondary
outcomes include direct and indirect costs of illness and
the predictors of chronic cough postpresentation.
Ethics and dissemination: The Children’s Health
Queensland (HREC/15/QRCH/15) and the Queensland
University of Technology University (1500000132)
Research Ethics Committees have approved the study. The
study will inform best-practice management of cough in
children.
Trial registration number: ACTRN12615000132549.
INTRODUCTION
Cough in children is one of the most
common reasons for medical encounters in
Australia1 and internationally.2 In the UK,
30% of hospital paediatric medical encoun-
ters (including emergency department (ED)
visits) are due to respiratory illnesses, with
cough as a symptom accounting for over 8%
of all presentations.3 Cough in children is
present in a broad range of respiratory ill-
nesses ranging from mild, self-limiting rhin-
itis to life-threatening acute and chronic
pulmonary disorders.4 Furthermore, acute
illness may bring to medical attention for the
ﬁrst time those with chronic underlying
disease. In the analyses of our recent cohort
study of 817 children (96% non-Indigenous)
aged <15 years presenting with cough to a
Strengths and limitations of this study
▪ Our study will be the first to assess the clinical
and economic impact of an early, evidence-
based intervention in the transitional stage from
acute to chronic cough in children.
▪ Conducting the study in primary care facilities
addresses the predominant setting in which
acute respiratory illnesses are managed.
▪ A limitation of the study is its generalisability to
children with acute respiratory illnesses in rural
and remote regions.
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tertiary paediatric ED,5 20% (95% CI 17.2 to 22.7) devel-
oped chronic (>4 weeks duration) cough after an acute
respiratory infection (ARI). Of those, 42% were diag-
nosed at specialist review with protracted bacterial bron-
chitis (PBB) and 32% were found to have a previously
undiagnosed respiratory disorder, including asthma,
large airway lesions (such as tracheomalacia), obstructive
sleep apnoea and bronchiectasis (unpublished).
Chronic cough in children is an under-recognised, but
important cause of morbidity and decreased quality of
life (QoL).6 Although an economic evaluation has never
been undertaken, chronic cough likely accounts for sub-
stantial direct and indirect economic costs.7 An
Australian study found that >80% of parents had sought
ﬁve or more medical consultations for their child in the
12 months immediately prior to referral to respiratory
specialists for their child’s chronic cough.7 Nevertheless,
there are few high-quality studies that address the
natural history of acute and chronic cough and none
completed that have a predominant focus on Australian
Indigenous children. Systematic reviews of the natural
history of acute cough in children in primary healthcare
found wide variation in the design and quality of
studies.8 9 There was large variability in the duration of
illnesses evaluated, how outcomes were measured and
completeness of follow-up. Importantly, in most studies
addressing acute cough in children, validated outcome
measures for cough were not used; those with prolonged
cough were not reviewed and there was no differenti-
ation between ‘wet’ and ‘dry’ types.9 Wet cough is
important as it implies increased airway secretions and
usually indicates clinically signiﬁcant lower airway infec-
tion and neutrophilic inﬂammation.10 11 For example,
chronic wet cough is the most common symptom of
bronchiectasis12 and early diagnosis and treatment
improves long-term outcomes.13 14
Indigenous people are at high risk of developing
chronic pulmonary disorders. Indeed, in nationwide
data for Indigenous Australians, respiratory disorders
are: (1) the most common reason for primary health-
care encounters; (2) the second most prevalent self-
reported chronic condition and (3) the second most
common cause for hospitalisation.15 Overall, 27% of
Indigenous people report some form of respiratory
disease; 19% in those aged <14 years and 38% in those
aged >55 years. In remote Indigenous children, the rates
of hospitalisation for ARI and radiographically diag-
nosed pneumonia,16 17 and the incidence of bronchiec-
tasis,18 are among the highest reported worldwide.
Recurrent ARI episodes are common17 and studies in
Indigenous children from central and northern
Australia demonstrated associations between these infec-
tions and subsequent diagnosis of bronchiectasis.19 20
To date, the focus on ARI has been largely on remote
Indigenous children, with limited community-based data
from those living in urban settings. This is despite socio-
economic and health indices being consistently lower
for urban Indigenous populations compared with
non-Indigenous groups.15 The lack of data on urban
and rural Indigenous populations has been identiﬁed as
a signiﬁcant barrier to ‘Closing the Gap’ initiatives.21
Although over half of the Indigenous population live in
urban and regional centres, most research addresses the
health and social issues of remote communities and only
11% of all articles about Indigenous health during a
5-year period addressed urban populations.21 However,
preliminary data from our ongoing cohort study of ARI
in young urban Indigenous children22 suggest 20% will
develop chronic cough post-ARI, principally from PBB.
Early detection and appropriate management of the
underlying aetiology (eg, bronchiectasis) causing
chronic cough in children is important as it results in
improved short23 and medium-term14 outcomes. Despite
the availability of evidence-based cough management
guidelines for children in several countries,24 25 includ-
ing Australia,26 the uptake and impact of the guidelines
is largely unknown. So far, only one randomised con-
trolled trial (RCT) has evaluated any of these guide-
lines27 28 and economic evaluation was absent. This was
conducted in ﬁve Australian cities where 272 children
(mean age 4.5 years, SD 3.7) newly referred to a paediat-
ric respiratory physician were randomly allocated to
either early review and use of a cough algorithm or
usual care until review and subsequent use of a prede-
ﬁned cough algorithm.27 28 The study28 found that chil-
dren in the ‘early-arm’ group had signiﬁcantly better
clinical outcomes (ie, cough resolution at week 6 postin-
tervention; absolute risk reduction=24.7%, 95% CI 13%
to 35%) and better cough-speciﬁc QoL compared with
the control group. However, in this study,28 the median
duration of cough at enrolment was 16 weeks (IQR 8–
32), and investigating earlier intervention is warranted.
Furthermore, the use of the cough algorithm in 346
children found that ∼18% had a serious underlying
illness. Indigenous children (10/34; 29.4%) were more
likely to have bronchiectasis than non-Indigenous chil-
dren (6.7%; 21/312; OR=5.78, 95% CI 2.15 to 14.5;
p<0.001).29
Despite the high burden of ARI, there are little pub-
lished data on interventions for acute and chronic
cough, especially for urban and regional Indigenous
children. An ARI sometimes unmasks a previously unrec-
ognised chronic respiratory illness, which is a major
problem in Indigenous Australians, but one that receives
limited attention.30–32 Early diagnosis and management
of chronic respiratory illness in children reduces mor-
bidity and improves QoL. This RCT will therefore
answer the primary question: ‘Amongst children aged
<15 years with chronic cough post-ARI, does active inter-
vention at 4 weeks improve clinical outcomes?’
Study objectives
Our primary objective is to determine if children aged
<15 years with chronic (>4 weeks) cough post-ARI and
managed according to an evidence-based cough
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algorithm have better clinical outcomes (faster cough
resolution) than those receiving standard care.
Our secondary objectives are to:
1. Determine the cost-effectiveness of early intervention
in chronic cough following an ARI compared to
standard care.
2. Identify the microbiological predictors of chronic
cough following an ARI.
3. Characterise the epidemiological, clinical, socio-
economic and cultural predictors of chronic cough
following an ARI.
4. Establish the epidemiological, clinical, socioeconomic
and cultural predictors of success or failure of an
early intervention in chronic cough following an ARI.
Our study tests the primary hypothesis that among
children aged <15 years with chronic (>4 weeks) cough
post-ARI, initiation of a cough management algorithm at
the transition from acute to chronic cough will reduce
cough duration.
METHODS AND ANALYSIS
Study design
A nested, open-label RCT (with concealed allocation)
within a prospective cohort study of children aged
<15 years presenting to three primary healthcare services
with an ARI that includes cough as a symptom, and who
are followed for 56 days (ﬁgure 1).
Eligibility
Inclusion criteria are:
▸ Aged <15 years,
▸ At the time of attending the clinic, the child is identi-
ﬁed as having a possible respiratory illness (including
those reported to have fever or viral/bacterial illness)
that has parent-reported cough as a symptom,
▸ Provision of written informed consent from the parent/
guardian and assent from children aged 12—<15 years,
▸ Siblings are permitted if each meets the above
criteria.
The exclusion criteria are: known diagnosis of an
underlying medical condition, including chronic pulmon-
ary disorders (excluding asthma); immunosuppressive
illness, such as primary immunodeﬁciency, HIV infection
or receiving immunomodulating drugs (except short-
course (<2 weeks) oral and ongoing maintenance inhaled
corticosteroids) in the 30 days prior to presentation;
current or planned participation in another intervention
study during the 8 weeks of follow-up; severe ARI requir-
ing hospitalisation, and/or insufﬁcient English inhibiting
provision of written informed consent or completion of
participant interviews.
Recruitment
Eligible children are identiﬁed when presenting to one
of three primary healthcare centres in subtropical,
Southeast Queensland, Australia, involving metropolitan
Brisbane (population 2.2 million), the regional city of
Toowoomba (110 000) and the rural town of Warwick
(14 000). Parents and their child(ren) will be approached
by clinic personnel and informed consent/assent
obtained using written and/or pictorial plain language
statements.
Data collection, follow-up and intervention
Children enrolled in each of the three primary health-
care centre cohorts undergo baseline clinical assess-
ments that include demographic details, medical history,
risk factors for ARI and cough, presenting features, vital
signs, investigations, treatment and cost-of-illness data
(ﬁgure 1). Weekly telephone and/or email and/or
face-to-face contacts collect cough status, type (ie wet,
dry variable) and cough score,33 medication (including
over-the-counter remedies) and health service provider
use for the cough and cost-of-illness data. Wet and dry
cough are classiﬁed as per parent/carer reports, which
Figure 1 Overview of study
design.
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were found previously to be accurate (compared with
respiratory physician and bronchoscopy) in a study of
children with chronic cough.34 The cost-of-illness data
are collected at each parent/carer contact, specialist
review and from examining medical records. A
minimum of three contact attempts are made at each
weekly time-point. We did not employ daily diary cards
as planned originally, since although their use in
chronic cough studies was reliable, we found that in chil-
dren with acute cough diary completion and return
rates were low during preliminary work undertaken for
this study. We also could not use smartphone apps as the
ownership of smart phones in the target communities is
low. Thus, instead we relied on weekly parent recall of
acute child illness, which has been shown to introduce
minimal bias (<10%) in prevalence studies.35
At day 28, any child with persistent cough (ie, ≤3 day
break in cough in the preceding 28 days) is randomised
(1:1 allocation) to clinical review and initiation of the
cough management algorithm or to continue weekly
follow-up. All study participants continue weekly follow-up
until day 56 and any child still coughing at that time point
undergoes clinical review until a deﬁnitive diagnosis is
established or the child exits the protocol. The decision to
follow children until day 56 was based on data from our
ED cough study, suggesting 42% of children with persist-
ent cough at day 28 will be diagnosed with PBB (manu-
script in preparation) that resolves with a 14-day course of
amoxycillin–clavulanic acid. Children requiring ongoing
care beyond two study physician reviews are referred to a
tertiary paediatric respiratory medicine service.
The study intervention involves study physician clinical
review within 2 weeks of day 28 where the cough man-
agement algorithm (ﬁgures 2 and 3) is implemented
depending on whether the child has a speciﬁc or non-
speciﬁc cough. Children in whom the cough has
resolved spontaneously between randomisation and
physician review, and at that point are deemed by the
study physician to require no further management, will
not contribute to the primary analysis.
Children in the control group follow a standard care
pathway. This reﬂects what occurs normally in the com-
munity for children with cough where the general
waiting period for review by a paediatric respiratory phys-
ician is on average 6 weeks following referral from a
family physician. The parents/guardians of children ran-
domised to the control group are advised to continue
follow-up with instructions that they will be reviewed by a
study doctor following day 56 if they are still coughing.
They are also counselled to seek advice from their family
physician or other healthcare provider if their child
becomes unwell or they are worried, otherwise to con-
tinue to self-manage their child’s cough as they see ﬁt.
Randomisation, allocation and blinding
An independent biostatistician prepared the randomisa-
tion code using a permuted blocking design (block size
of 4) to maintain group balance. Randomisation was
stratiﬁed by reason for presentation (ARI with cough or
another reason with an ARI noted incidentally), site and
cough duration at day 28 (<6 or ≥6 weeks). Group alloca-
tion is concealed in opaque, consecutively numbered
Figure 2 Specific cough
pathway.
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envelopes kept in a locked cabinet at the Centre for
Children’s Health Research, South Brisbane. At random-
isation, the child’s cough history over the past 28 days and
study-speciﬁc strata are conﬁrmed by the Central
Coordinating Site. The Study Coordinator selects the next
consecutively numbered, opaque, sealed envelope from
the relevant strata pack, opens the envelope and extracts
the randomisation code. Two people check the allocation
and the code is assigned to the participant. The Study
Coordinator then arranges for the study physician to
review within 2 weeks of randomisation those children allo-
cated to the intervention arm. If siblings are also enrolled
and each child is still coughing at day 28, randomisation
occurs for the ﬁrst child enrolled (ie, earliest study
number) and all siblings are allocated subsequently to the
same arm. Differences in strata (eg presentation type and
cough duration) will be accounted for in the analysis.
Blinding is not undertaken in this study; however,
parents are not informed at enrolment that their child
will be randomised at day 28 to a speciﬁc intervention if
the child has a persistent cough. Instead, they are
informed that children who develop persistent cough
will be reviewed by a paediatrician during the study with
some children being seen earlier and some later in the
8-week follow-up period. Limited disclosure is permitted
under the Australian ethical standards for human
research36 if it is scientiﬁcally justiﬁable and does not
present an increased risk of harm to the participant.
Figure 3 Non-specific cough
pathway.
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Definitions
Deﬁnitions used for the clinical management
pathway23 27 are as follows:
▸ Asthma: recurrent (>2) episodes of wheeze and/or
dyspnoea that responds (within minutes) to inhaled
β2 agonist or demonstrates bronchodilator responsive-
ness documented on spirometry (≥12% change in
the percentage predicted forced expiratory volume in
1 s after 400 µg of salbutamol).
▸ Cough resolution: improvement ≥75% or total reso-
lution according to cough diary data for ≥3 consecu-
tive days.37 38 When cough diary data are unavailable,
resolution is deﬁned as total cessation of cough
according to parent/guardian verbal report.
▸ Chest radiograph abnormality: any abnormality (other
than peribronchial thickening) identiﬁed by a paediat-
ric respiratory physician or radiologist.
▸ Spirometry abnormality: as determined by the
American Thoracic Society and European Respiratory
Society criteria with Australian predicted values used.39
▸ Primary diagnosis of cough aetiology: diagnosis con-
ﬁrmed by subsequent speciﬁc treatment that resulted
in cough resolution within 3 weeks.26 37 The diagnos-
tic criteria are deﬁned a priori following published
guidelines:6
– PBB: presence of an isolated chronic wet or pro-
ductive cough, without signs of another cause and
which responds to at least a 2 weeks course of an
appropriate antibiotic, such as
amoxicillin-clavulanate.
– Recurrent PBB: ≥3 episodes over a 12-month
period.
– Reversible airway obstruction: in accordance with
American Thoracic Society and European
Respiratory Society criteria and adopting Australian
predicted values.39
Secondary diagnosis: diagnosis found on objective tests,
but where: (1) speciﬁc treatment did not lead to reso-
lution or improvement in the cough; or (2) no treat-
ment for this diagnosis was trialled and the cough
either resolved spontaneously or with other therapies.6
Speciﬁc cough pointers: presence of any of the follow-
ing: auscultatory abnormality (wheezes, crackles or
differential breath sounds), classical cough character-
istics, cardiac abnormalities, chest pain, chest wall
deformity, daily moist or productive cough for
>3 months, digital clubbing, dyspnoea (exertional or at
rest), failure to thrive, feeding difﬁculties (including
choking/vomiting), haemoptysis, immune deﬁciency,
neuro-developmental abnormality, recurrent pneumonia
and wheeze. These pointers are explained in the
Thoracic Society of Australia and New Zealand position
statement.37
Tertiary hospital management: that usually requires
investigations to be conducted at a paediatric tertiary
centre (eg, ﬂexible bronchoscopy with bronchoalveolar
lavage, chest high-resolution CT scan, ﬂuoroscopic
swallow screening, etc).
Specimen collection
At recruitment, exhaled carbon monoxide (eCO) mea-
sures from the child (if aged ≥ 3 years and can provide
an adequate sample) and parent/guardian are collected
to provide an objective, non-invasive assessment of cigar-
ette smoking status and exposure40 using a portable
eCO monitor (Smokerlyzer, Bedfont Scientiﬁc,
England).
All children have bilateral anterior nasal swabs col-
lected at enrolment and at days 28 and 56. Anterior
nasal swabs rather than nasopharyngeal swabs are being
used as: (1) they are more acceptable to children; (2) in
our experience have comparable sensitivity to nasopha-
ryngeal specimens41 and, besides, any loss in sensitivity is
considered acceptable when the purpose of the speci-
men is epidemiological rather than for a clinical diagno-
sis42 and (3) they permit more extensive swabbing of the
nares. Nasal swabs are collected using Virocult plain
cotton tip swabs with viral transport medium (Virocult,
MW951, Medical Wire and Equipment, England)
inserted 1 cm into the nostril and rotated four times on
the right side and then on the left side. Swabs are stored
locally in −20°C freezers before being transported to the
research laboratory where they are stored at −80°C until
processing occurs.
Laboratory methods
Swabs are batch-tested for respiratory viruses and bac-
teria using validated real-time PCR assays described pre-
viously.42 43 Virus testing includes rhinoviruses, adenovirus,
respiratory syncytial virus, inﬂuenza virus types A and B,
parainﬂuenza virus types 1–3, human metapneumovirus,
human coronaviruses (OC43, 229E, NL63, HKU1), human
bocavirus and human polyomaviruses KI and WU. Bacterial
testing includes Bordetella pertussis, Mycoplasma pneumoniae,
Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus
inﬂuenzae (including differentiating between encapsulated
and non-encapsulated strains and Haemophilus haemolyticus)
and Moraxella catarrhalis.
End points
Participation is completed 56 days (+3 days) following
enrolment or, for children in the RCT, when a ﬁnal diag-
nosis is determined by the study physician. Other exit
points are serious protocol violations and worsening of
the child’s condition that requires hospitalisation or
other active intervention elsewhere. Children meeting
the exit criteria will continue to be followed until the
end of the study period.
Outcome measures
Primary clinical outcome: Time-to-cough resolution in days.
Secondary cost-effectiveness outcomes: Total direct and indir-
ect costs of illness calculated according to the criteria
outlined in table 1.
Secondary microbiological outcomes: Anterior nasal detection
by PCR of respiratory viruses and bacteria at days 28
and 56.
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Sample size
Sample sizes for each of the primary healthcare cohorts
comprising this study are based on the expected
number of eligible children with ARI presenting to each
of these services over the study’s timeframe and derived
from our current studies of chronic cough post-ARI in
children.22 52 Between July 2015 and June 2017, we
anticipate 750 eligible children will present to the
primary healthcare services participating in this study.
Our preliminary data from a cohort study of
Indigenous children aged <5 years22 suggest 20% of
Indigenous children with an ARI will have chronic
cough at day 28. Based on data from the ﬁrst study of
the algorithm28 for the primary end point of cough reso-
lution at day 56, we anticipate a 54% reduction in the
proportion of children (54.3% in the early arm com-
pared with 29.5% in the delayed arm) with persistent
cough at day 56. Hence, 89 children per group with
complete evaluable data at day 56 will provide 90%
power (α=0.05), to detect this 54% reduction for our
primary aim. Assuming a 20% loss to follow-up and
spontaneous resolution of cough of between randomisa-
tion and physician review of 5%, we will therefore ran-
domise a minimum of 112 children per group at day 28
across all 3 sites.
Given that the entire cohort study will have a 2-year
recruitment period, and the natural history and
predictors of chronic cough and cost-effectiveness of the
intervention are important secondary outcomes, we will
not limit recruitment to the RCT arm once 224 children
have been randomised. Ongoing enrolment will hence
increase study power to address the primary and second-
ary objectives. This approach has approval from the all
relevant human research ethics committees (HREC).
Data management
Data will be entered into a password-protected, custom-
built, Filemaker Pro Advanced V.14 (Filemaker, Santa
Clara, USA) database. The database has been designed
to incorporate automatic data checking including logic
and inaccurate ranges and maintains a log of any
changes to the data. Data ﬁelds cannot be left blank and
missing data must be coded as such in the database. A
speciﬁc data management protocol compliant with the
Queensland University of Technology’s data manage-
ment policies and principles is in place.
Statistical methods
Data will be presented in accordance with the updated
CONSORT criteria.53 Demographic, clinical, economic,
risk factor and microbiological data will be tabulated for
the study population overall, by centre and by random-
isation group and expressed as proportions and/or
means of the selected characteristics by study centre,
Table 1 Cost item, sector allocation and source of cost used in costing acute and chronic cough
Cost item Sector Source of cost to be applied
Healthcare service usage
▸ Includes costs for diagnostic tests and complementary/
alternative therapies
▸ Distinguishes between public and private, paid and
bulk-billed services
Family
Healthcare
Health
insurers
Manual of resource items and their
associated costs44
National Hospital Costs Data Collection45
Quarterly Gap Payment and Medical Benefits
Statistics46
Medicare Quarterly Statistics47
Medicare Benefits Schedule48
Expert panel or large online provider where
required
Medication usage
Includes over-the-counter and prescribed medications
Family
Healthcare
Pharmaceuticals Benefits Scheme (PBS)49
Online providers when not listed on PBS
Healthcare seeking travel costs
Includes ambulance and community transport services
Family Parental Report
Private Health Insurance Administration
Council50
Petrol: average unleaded retail price
Translink: average ticket prices
Time spent seeking healthcare
▸ Time off work with pay
▸ Time off work with pay lost
▸ Time off usual activity
Family
Employers
Parental report
Average weekly earnings, Australia51
Extra time spent caring for child
▸ Time off work with pay
▸ Time off work with pay lost
▸ Time off usual activity
Family
Employers
Parental report
Average weekly earnings, Australia51
Missed childcare/school Family Parental report
Missed planned activities
Child and others
Family Parental report
Costs will be applied following the completion of data collection ensuring up-to-date cost data.
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and presence/absence of chronic cough at day 56 with
the corresponding 95% CI. Differences between groups
will be assessed using t-tests for comparisons of means
and χ2 test for comparisons of proportions, conditional
on test assumptions for each being satisﬁed. Non-normally
distributed data will be analysed with appropriate
non-parametric tests.
Primary objective
Intention-to-treat analyses will be employed. Time-
to-cough resolution will be compared between groups
using the Cox proportional hazard methods, adjusting
for independent explanatory variables, subject to model-
ling assumptions being met, particularly proportionality
of hazards. All analyses will be performed on the whole
cohort and then additional analyses will be performed
using frailty models54 that account for the clustering
effects of siblings and site of recruitment.
Economic objectives
Costing of the intervention will be performed according
to established methods,55 56 including detailed subana-
lyses of data that account for epidemiological, social,
cultural, risk factor and microbiological variables.
Cost-effectiveness analysis (CEA) will be modelled using
the health sector perspective. Broader societal issues
using data from the trial as described above and aug-
mented by the evidence from the literature, especially
systematic reviews, will also be taken into consideration.
The CEA approach will involve: identiﬁcation of
resources using the intervention pathway (activities,
probabilities and unit costs); measurement of resource
use/outcomes; and valuation of costs using unit costs
published in the literature and from the trial itself. The
time horizon will be speciﬁed and current practice
(standard care) will be the comparator; and future costs
and beneﬁts will be discounted at 3% to present values.
Central to this analysis will be the modelling of uncer-
tainty surrounding data quality and gaps using sensitivity
analyses, and extension of time horizon, using Treeage
software (Treeage Software, Williamstown, Massachusetts,
USA). The key outcomes will be incremental cost-
effectiveness, and cost-savings to the health system due
to the interventions.
Other objectives
Multivariable modelling will be employed to: (1) evalu-
ate the microbiological predictors of chronic cough fol-
lowing an ARI as determined at days 28, 42 and 56
postenrolment; (2) evaluate the epidemiological, clin-
ical, socioeconomic and cultural predictors of chronic
cough at day 28 post-ARI; (3) evaluate the epidemio-
logical, clinical, socioeconomic and cultural predictors
of success or failure of the intervention at day 56 and
(4) to compare these predictors between the three study
populations. Crude and adjusted relative risks and the
respective 95% CIs will be presented, with differences
considered statistically signiﬁcant at p<0.05.
Subgroup analyses will be performed for all primary
and secondary objectives to examine potential differ-
ences by study-speciﬁc strata. Univariate and multivariate
analyses will be performed to evaluate variables inde-
pendently associated with study end points and to assess
potential confounding factors in the association between
vaccination and disease. Multiple imputation models will
be used to evaluate the effect of missing data. Additional
analyses will be undertaken to assess the effect of multi-
plicity in the assessment of microbial associations with
cough outcomes.
Participant safety
Parents/guardians of all participants will be informed of
any new information that arises during the study that
may indicate potential harm to the child if he/she were
to continue in the study. Any trial-related adverse events
will be documented and reported to the relevant HREC.
Serious adverse events will be reported to the HREC
within 24 hours of notiﬁcation and will be followed until
resolution. A decision to withdraw the child following a
serious adverse event will be made in consultation with
the HREC, investigating team and the child’s primary
physician. If an adverse event is deemed related to study
procedures, the child and his/her family will be eligible
for compensation under the Clinical Trial Insurance pol-
icies in place for the duration of the study. All partici-
pant data will be kept conﬁdential and stored securely in
accordance with Australian Privacy Laws. Identifying
data will not be provided to any persons outside of the
study team unless required by Australian law (eg, in the
event of the diagnosis of a notiﬁable disease). Published
data will be deidentiﬁed and presented in aggregate
form.
Independent monitoring and quality control
Independent study monitors have been engaged to
undertake regular data quality audits, assess compliance
with Good Clinical Practice guidelines and ensure that
the study is being conducted according to the study
protocol and ethical approvals. Inbuilt data quality mon-
itoring and generation of data queries are established
within the trial database, with data queries sent to study
sites weekly for resolution.
Protocol amendments
All protocol amendments will be submitted to the study’s
HREC (see below) for approval prior to implementation.
If any amendments have the potential to affect a family’s
willingness to continue in the study, all participants will
be reconsented to the amended protocol.
Study status
Recruitment began in July 2015.
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DISSEMINATION
Participants will be provided with regular study progress
reports and a written letter outlining the results of the
study. The trial results, including any negative ﬁndings,
will be published in open-access peer-reviewed journals
and presented at scientiﬁc conferences, paediatric
society and general practitioner meetings and other
fora. The primary author of the main paper will be the
principal investigator (KFO). The trial ﬁndings are likely
to be incorporated into clinical management guidelines.
Study data will be held in metadata repositories until the
youngest child turns 25 years of age at the Queensland
University of Technology. Deidentiﬁed study data will be
made available to external parties on request and, if
relevant, with the appropriate HREC approvals.
DISCUSSION
Chronic cough in children is a deﬁning symptom of
several chronic pulmonary disorders worldwide.
Preventing persistent cough in children may lead to
important short and long-term health beneﬁts. Our pro-
posed intervention22 26 is similar to the existing
Australian guidelines,57 but also has some differences
that were developed following the incorporation of new
data unavailable at the time the guidelines were pub-
lished. The use of guidelines by clinicians depends on
several factors, which include level of evidence, feasibil-
ity, degree of implementation and inherent clinician
factors.58 Using an algorithm facilitates clinical guideline
implementation by clearly describing pathways of care
based on whether the child presents with a speciﬁc or
non-speciﬁc cough. While this study uses speciﬁc study
physicians, the overall goal is widespread adoption of
the guidelines and management algorithm in the
primary healthcare setting. Our extensive data collec-
tion, including direct and indirect costs of illness and
healthcare provision, are important in achieving this
goal. The study will also provide an avenue for assessing
the extent to which these guidelines are being used cur-
rently in different clinical settings given. We will collect
data on any intervention a child may receive external to
our study.
Study site selection was based on several factors,
including existing relationships, feasibility and how they
incorporated geographically and demographically differ-
ent Indigenous communities. Studies evaluating ARI
and chronic cough have had differing study designs,
objectives and end points between populations.
Australian data suggest cough burden is independent of
age and aetiology, but dependent on clinical setting.29
In Australia, there are clear risk and burden distinctions
between children from urban and remote areas and
between Indigenous and non-Indigenous children.59
Indigenous children in urban areas have received much
less attention than those in remote centres. Failure to
account for these differences may lead to inappropriate
interventions or implementation of management guide-
lines that may not be applicable across all settings.
The economic data and analyses in this study will be
the ﬁrst to describe the cost of ARI and its outcomes in
Indigenous children in Australia, and one of the few
worldwide. Further, the CEA of the intervention will
provide data critical to clinical and public policy deci-
sions with respect to incorporation of the intervention
into routine care at the primary and tertiary healthcare
levels. Such decisions will be enhanced by our incorpor-
ation of direct and indirect costs to the family, the com-
munity and the healthcare sector,60 particularly given
the focus on resource allocation in Indigenous health in
Australia,61 and the different mechanisms for delivery of
primary healthcare services compared with mainstream
Australia.62
We have incorporated microbiological components
into the RCT as the role of infectious agents in the tran-
sition from ARI to chronic wet cough remains largely
unknown. Whether persistent shedding, new acquisition
and/or virus–bacteria interactions are associated with
the development of chronic cough post-ARI is a clinical
and research gap needing to be addressed. A study of
170 children aged 5–16 years presenting to their family
physician with a cough lasting >14 days detected M. pneu-
moniae and B. pertussis in 12.9% and 36.6%,
respectively.63 Cough duration was shorter in M. pneumo-
niae than B. pertussis cases and codetection with respira-
tory viruses was not associated with cough duration.63
An important limitation of this study63 was that data
were not collected from the time of ARI onset. Other
studies64 have also tested for bacteria and viruses in
nasopharyngeal specimens, but to date none have fol-
lowed children from ARI onset and examined the associ-
ation with developing chronic cough. In the analyses of
microbiological data collected in our study of children
attending an ED with cough, M. cattarhalis detected by
PCR in anterior nasal swabs collected at time presenta-
tion was the only organism independently associated
with persistent cough at 4 weeks after controlling for
age, gender and the presence of any viruses.5 Our
Brisbane-based lower airway studies of children with
chronic cough from PBB found intense neutrophilic
airway inﬂammation and evidence of innate immune
activation, suggesting that PBB may follow a single ARI
episode with impaired pathogen clearance from the
airways, either permanently or temporarily leading to a
cycle of chronic inﬂammation.65 Small case series from
the late 1990s have reported chronic pulmonary seque-
lae following inﬂuenza infection in young children66
and a relationship between adenovirus infection and
bronchiectasis.67
The major threats to the validity of our proposal are
loss to follow-up and potential for contamination of the
control group based on the type of standard care they
may receive. In our current ARI study in urban
Indigenous children, loss to follow-up at the 4-week time
point post-ARI is 23%. Procedures to minimise this loss
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include: home visiting by Indigenous research person-
nel, regular text and email messaging, and personal
letters to families. Analysis plans will include measures to
account for missing data and sensitivity analyses to assess
the extent of bias.
Although contamination of the control group is pos-
sible, based on a multicentre RCT conducted in ﬁve
major Australian cities,29 it is unlikely that a child in
standard care will receive treatment similar to the inter-
vention arm. In another of our studies,52 just 27% of
children sought further medical advice for cough in the
4 weeks following presentation to an ED for an illness
with cough as a symptom (unpublished data).
Furthermore, of the 9.7% receiving antibiotics during
this 4-week period,5 most were prescribed antibiotics at
the time of the original ED presentation. Hence, it is
unlikely this will inﬂuence the validity of our RCT for
several reasons: (1) We can assess any intervention
either group receives outside of the RCT since our
weekly follow-up data collection captures these events.
(2) In the possible, but unlikely event of a change in
treatment in the control group, the effect size of the
intervention will be smaller requiring a larger sample
size. The a priori sample size is conservative with 90%
power and a smaller effect size will still be detectable
within the available study population (eg, a 35% differ-
ence with power of 80% requires 114 per group). (3) To
ensure robustness, an independent person will recalcu-
late the sample size when 50% of children have com-
pleted the RCT component.
In summary, our RCT will be the ﬁrst to examine the
impact of a cough management algorithm implemented
at the transitional stage from acute to chronic cough in
Indigenous children. Clinical effectiveness will be evalu-
ated concurrently with detailed epidemiological, clinical,
microbiological and economic determinants of ARI and
cough persistence in this population. If successful, the
study may provide the data necessary to facilitate the
uptake and implementation of cough management
guidelines in the primary healthcare setting, potentially
reducing the long-term burden of disease on the child,
family, community and healthcare sector.
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